WHO just approved a major shift in HIV prevention — and it comes as the world stalls on progress.

By Aniket Chakraborty

July 16, 2025

Arrow

HEALTH & WELLNESS

Arrow

Meet lenacapavir: a twice-a-year injection offering near-total protection against HIV.

2

Arrow

The FDA greenlit it recently — and now WHO is urging global rollout in high-risk regions.

3

Arrow

It’s a breakthrough for those struggling with daily pills, stigma, or health access gaps.

4

Arrow

The science is solid: lenacapavir disrupts HIV at multiple stages using capsid inhibition.

5

Arrow

But access won’t be easy — Trump’s U.S. aid cuts have gutted HIV funding globally.

6

Arrow

PrEP use has already collapsed in countries like Nigeria since the cuts began.

7

Arrow

WHO also recommends rapid-test models and pharmacy-based delivery to simplify care.

8

Arrow

Gilead will supply the drug at cost through the Global Fund — but only in select regions.

9

As vaccine hopes stall, lenacapavir may be our best shot — if the world can afford it.

10